Thermo Fisher Scientific Capabilities Update April 2026: Small Molecule Drug Product

Oral dose programs often move quickly in early development, with attention centered on generating clinical data, conserving API, and reaching the next milestone. In that push to advance, what sometimes receives less scrutiny is how early formulation and process decisions will perform at scale.

When those downstream implications are not examined early, programs can encounter avoidable friction during scale-up, technology transfer, or validation. This dynamic can be particularly challenging for newer and emerging biotech teams, where limited internal CMC bandwidth and reliance on external partners make early technical alignment even more critical. Speed alone does not guarantee continuity.

This session examines how to connect formulation design, process development, and scale strategy from the outset, aligning early technical decisions with the realities of larger batch sizes, different equipment platforms, and commercial manufacturing requirements. The focus is on reducing iteration, protecting timelines, and creating a clear progression from Phase I through commercialization.